Biotech Firms, Billions at Risk, Lobby States to Limit Generics »

Share on Facebook

Share on Twitter

The industry’s lobbying effort could blunt new competition to its products and reduce the savings anticipated in the federal health care overhaul. Source Main page (current trends)

More about: Biotech Firms, federal health care, Lobby States

Share on Facebook

Share on Twitter

Your comments